FMED — Fidelity Disruptive Medicine ETF
Data updated: 2026-07-24
FMED — Fidelity Disruptive Medicine ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Thematic Equity · $40.98M AUM · 0.50% expense ratio · 8.0% 1-yr return. From SEC regulatory filings.
FMED Fund Overview
FMED — Fidelity Disruptive Medicine ETF is a US ETF managed by Fidelity Covington Trust, categorised as United States Thematic Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Fidelity Covington Trust
- Category: United States Thematic Equity
- Assets under management: $40.98M
- 1-year return: 8.0%
- Ticker: FMED
- SEC CIK: 0000945908
- SEC series ID: S000079688
- Share class ID: C000240928
FMED Holdings
Top 10 holdings of Fidelity Disruptive Medicine ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Fidelity Revere Street Trust | 10.27% |
| Ucb SA | 4.73% |
| Lifestance Health Group, Inc. | 4.27% |
| Danaher Corp. | 3.42% |
| 10x Genomics, Inc. | 3.11% |
| Intuitive Surgical, Inc. | 2.92% |
| Cogent Biosciences, Inc. | 2.85% |
| Alnylam Pharmaceuticals, Inc. | 2.79% |
| Argenx SE | 2.78% |
| Legend Biotech Corp. | 2.29% |
FMED Portfolio Allocation
Asset-class allocation of Fidelity Disruptive Medicine ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.7% |
| Cash & Equivalents | 10.6% |
FMED Performance
Total returns for FMED (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -6.9% |
| 1 year | 8.0% |
| 3 years (annualised) | 0.3% |
FMED Risk Information
Risk metrics for FMED, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 15.0%
FMED Costs and Fees
FMED costs about $50 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.50%
- Gross expense ratio: 0.50%
- Portfolio turnover: 30%
- Brokerage commissions: 1.99 bps of average net assets (SEC N-CEN)
FMED Cashflows
Over the 12 months to 2026-02, Fidelity Disruptive Medicine ETF had net inflows of $5.12M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | $0 |
| 2026-01 | $0 |
| 2025-12 | $2.76M |
| 2025-11 | $0 |
| 2025-10 | $0 |
| 2025-09 | $0 |
FMED Debt Constituents
No individual debt constituents are reported in Fidelity Disruptive Medicine ETF's latest SEC N-PORT filing.
FMED Prospectus and SEC Filings
Official Fidelity Disruptive Medicine ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Thematic Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.